^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HRS-2189

    i
    Other names: HRS-2189, HRS2189, HRS 2189
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    KAT6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fudan University
    New P2 trial
    |
    AiRuiLi (adebrelimab) • HRS-2189
    1year
    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-2189
    over1year
    Study of HRS-2189 Combined HRS-5041 in Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    HRS-2189 • HRS-5041
    over1year
    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov)
    P1/2, N=300, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    HRS-2189
    over2years
    Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    HRS-2189
    almost3years
    Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    HRS-2189